Aspects on sepsis : treatment and markers

DSpace Repository

Aspects on sepsis : treatment and markers

Show simple item record

Full item record

dc.contributor.author Gustafsson, Anna
dc.date.accessioned 2012-02-10T10:21:08Z
dc.date.available 2012-02-10T10:21:08Z
dc.date.issued 2012 en_US
dc.identifier.citation 72 s.
dc.identifier.isbn 978-91-7104-428-0
dc.identifier.issn 1653-5383 en_US
dc.identifier.uri http://hdl.handle.net/2043/13382
dc.description.abstract Sepsis is one of the greatest challenges in critical care medicine today, while the treatment of sepsis and evaluation of its severity is complicated. The first part of this thesis presents two approaches on the use of antimicrobial peptides in sepsis treatment, relying on both soluble and immobilized peptides. All peptides tested, truncated from human and non-human antimicrobial peptides, did neutralize LPS activity in a dose-dependent manner. Immobilization of the peptides did not inhibit their ability to bind LPS, therefore, the peptides can be considered for extracorporeal LPS removal in sepsis therapy. Interestingly, the soluble peptides inhibited LPS induced cytokine production but potentiated LTA induced cytokine production in human blood. Consequently, care should be taken when considering these peptides in treatment of Gram-positive infections. The second part of this thesis evaluates the inflammatory marker soluble urokinase plasminogen activator receptor (suPAR) in sepsis prognosis. Also, an investigation whether suPAR can be detected in human saliva was undertaken. The results indicate that plasma levels of suPAR are increased in sepsis patients compared to controls, but there was no significant difference between survivors and non-survivors. Plasma levels of suPAR did not correlate with other inflammatory markers, suggesting that suPAR reflects general activation of the immune system rather than exerting inflammatory actions. Moreover, suPAR can be detected in saliva and the levels are more than 10 times higher than the corresponding plasma levels in healthy individuals.
dc.language.iso eng en_US
dc.publisher Malmö University. Faculty of Health and Society
dc.relation.ispartofseries Doctoral Dissertation;2
dc.relation.haspart Gustafsson A. Olin AI., Ljunggren L. LPS interactions with immobilized and soluble antimicrobial peptides. Scand J Clin Lab Invest. 2010;70:194-200
dc.relation.haspart Gustafsson A, Sigel S, Ljunggren L. The antimicrobial peptide LL37 and its truncated derivatives potentiate proinflammatory cytokine induction by lipoteichoic acid in whole blood. Scand J Clin Lab Invest. 2010;70:512-8
dc.relation.haspart Gustafsson A, Ljunggren L, Bodelsson M, Berkestedt I. The prognostic value of suPAR compared to other inflammatory markers in patients with severe sepsis. Biomarker Insights. 2012;7:39-44
dc.relation.haspart Gustafsson A, Ajeti V, Ljunggren L. Detection of suPAR in the saliva of healthy young adults: comparison with plasma levels. Biomarker Insights. 2011;6:119-25
dc.subject antimicrobial peptides
dc.subject cytokines
dc.subject lipoteichoic acid
dc.subject lipopolysaccharide
dc.subject soluble urokinase plasminogen activator receptor
dc.subject sepsis
dc.subject.classification Medicine en_US
dc.title Aspects on sepsis : treatment and markers en_US
dc.type Doctoral Thesis
dc.identifier.paperprint 1 en_US
dc.contributor.department Malmö University. Faculty of Health and Society en
dc.subject.srsc Research Subject Categories::MEDICINE en_US
 Find Full text

Files for download

Thesis without ...

This item appears in the following Collection(s)

Show simple item record

Search


Browse

My Account

Statistics